Immune Modulation by Exosomes in COVID-19 (IMECOV19)

University of Ulm

Status: Enrolling

Conditions: COVID-19; Critical Illness; Hypercytokinemia; Lung Fibrosis

Treatments: Biological: Application of exosomes in a whole blood assay

Study type: Observational

Funder types: Other

Identifiers

NCT05191381

Lung fibrosis in COVID19

Details and patient eligibility

About

Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.

Full description

Critically ill patients with COVID-19 may develop lung failure and require extracorporal oxygenation due to hyperinflammation and progressive lung fibrosis. The anti-inflammatory and immune modulatory function of mesenchymal stem cells will be investigated by whole blood stimulation experiments using stem cell derived exosomes. Exosome preparations have been characterized by miRNA and protein expression patterns and suggest their tissue regenerative capacity.

The hypothesis of the present study is that mesenchymal stem cell derived exosomes attenuate inflammation and support anti-fibrotic pathways.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Critically ill COVID-19 patients with lung dysfunction
• COVID-19 WHO severity degree >= 4, ARDS (WHO Definition 13 March 2020)
• Body weight > 50 kg
• Informed consent

Exclusion criteria

• Pregnant or breast feeding women